section name header

Information

Author(s): Marlies Ostermann and David Sprigings

Acute kidney injury (AKI), formerly known as acute renal failure, is a syndrome characterized by an abrupt (within hours to days) deterioration in renal function. It is defined by a rise in serum creatinine or reduction in urine output, or both (Box 25.1 and 25.2). AKI occurs in around 10–20% of patients admitted to hospital, and is most often due to hypovolaemia/hypotension, sepsis and nephrotoxins (Tables 25.1 and 25.2).

Priorities

Stage-based management of AKI is summarized in Figure 25.1. Consider and address potentially correctable causes or contributory factors (Tables 25.1 and 25.2):

  1. Correct hypovolaemia/hypotension
    • Prompt and vigorous correction of hypovolaemia and hypotension will often reverse AKI. If there is clinically obvious hypovolaemia, give IV fluid (crystalloid or blood, as appropriate to the cause of hypovolaemia). A CVP line may be helpful (to avoid over-replacement of fluid), but the patient should be resuscitated first before this is placed.
    • If the evidence for hypovolaemia is less certain, but there are no clinical signs of fluid overload, give a fluid challenge, ideally with monitoring of the CVP, especially if the JVP is difficult to assess. Target CVP is 5–10cm water, measured from a mid-axillary line zero reference point (p. 662). Ultrasonography of the inferior vena cava is an alternative method of assessing the CVP.
    • If the systolic BP remains <90 mmHg despite correction or exclusion of hypovolaemia, search for and treat other causes of hypotension, of which sepsis is the most likely (Chapter 35). If the BP remains low, inotropic-vasopressor therapy will be needed (p. 13 Table 2.7).
  2. Search for and treat sepsis
    • Suspect sepsis if AKI is associated with fever or reduced body temperature (<36°C), or there is an obvious focus of infection (e.g. signs of pneumonia or recent instrumentation of urinary or biliary tract). Bear in mind that many patients with neutropenic sepsis (Chapter 101) have no detectable clinical focus. Obtain a surgical opinion if you suspect an abdominal or pelvic source.
    • The diagnosis and management of sepsis is described in Chapter 35. Start antibiotic therapy as soon as blood has been taken for culture and within one hour. Choice of antibiotic therapy should take account of the source of sepsis, if known, whether the infection is community or hospital acquired, results of previous isolates from the patient and the local pattern of antibiotic resistance.
  3. Exclude urinary tract obstruction
    • Ultrasonography should be performed within 24h if obstruction is suspected or there is no identified cause of AKI. It should be performed as soon as possible in case of suspected pyonephrosis or obstruction of a solitary kidney. Non-contrast CT is an alternative to ultrasonography.
    • AKI beginning in hospital is rarely due to urinary tract obstruction, once bladder outflow obstruction has been excluded by catheterization. The hallmark of obstruction is dilatation of the urinary tract above the obstruction, although this is not an invariable feature.
  4. Treat immediate complications of AKI

Severe Hyperkalaemia

  • If there are ECG changes of hyperkalaemia, give 10 mL of 10% calcium gluconate 10% IV.
  • If serum bicarbonate is <22 mmol/L and there is no fluid overload, give 500 mL of 1.26% sodium bicarbonate IV over 1–2h.
  • If plasma potassium is >6.5 mmol/L or there are ECG changes, give insulin 10 units in 50 mL of 50% glucose over 15 min; salbutamol 10 mg by nebulizer may also help (these measures will reduce plasma potassium for <4h).
  • Stop potassium supplements or any drugs (e.g. ACE-inhibitors, potassium-retaining diuretics) which may be contributing to hyperkalaemia.
  • If renal function is not improving despite vigorous management of correctable factors, renal replacement therapy will be needed; discuss this with your renal unit or ICU early before any life-threatening complications of AKI occur.

Pulmonary oedema

  • Sit the patient up and give oxygen 60–100%, aiming for an oxygen saturation >94%.
  • Give furosemide 80 mg IV.
  • If systolic BP is >110 mmHg, start a nitrate infusion.
  • Look for underlying heart disease; investigation should include an ECG and echocardiogram.
  • Further management of pulmonary oedema is described in Chapter 47.

Further Management

Outline


Monitoring and supportive care in AKI is summarized in Table 25.5. Three common scenarios are encountered:

Corrected Hypovolaemia/Hypotension, with Improving Renal Function!!navigator!!

  • Management is that of the underlying disorder, taking care to avoid hypovolaemia and nephrotoxic drugs (Table 25.2).
  • Make sure all drug dosages are adjusted appropriately: consult the section on Prescribing in renal impairment in the British National Formulary.

Persisting/Worsening AKI Despite Correction of Hypovolaemia/Hypotension and Removal of Nephrotoxins!!navigator!!

  • These patients should be discussed with your renal unit and/or intensive care unit. They need a definitive diagnosis, and may require renal replacement therapy. Indications for renal replacement therapy are summarized in Table 25.6.
  • After haemodynamic resuscitation and removal of nephrotoxins, no specific therapy has been shown to be protective in AKI. Low-dose dopamine is not effective. Loop diuretics should only be used if there is fluid-overload.

Suspected Urinary Tract Obstruction!!navigator!!

  • Ask advice from a urologist. A bladder catheter should be inserted if there is bladder outflow obstruction. Percutaneous nephrostomy drainage may be indicated if there is ureteric obstruction.

Further Reading

Floege J, Amann K (2016) Primary glomerulonephritides. Lancet 387, 20362048.

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO (2012) Clinical Practice Guideline for Acute Kidney Injury. Kidney Int 2 (suppl 1), 1138.

National Institute for Health and Care Excellence (2013) Acute kidney injury: prevention, detection and management. Clinical guideline (CG169). https://www.nice.org.uk/guidance/cg169?unlid = 429931086201692925215.